Compare Stocks → Wall Street Legend Issues New NVDA Warning (From Chaikin Analytics) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AEMDOTCMKTS:ARTHNASDAQ:NVCNNASDAQ:NVIV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.53+1.2%$1.65$1.35▼$5.00$4.01M1.888,279 shs619 shsARTHArch Therapeutics$1.18+3.5%$1.91$0.39▼$18.00$5.59M3.523,850 shs618 shsNVCNNeovasc$30.03$29.69$4.59▼$30.07$82.28M1.756,993 shs1 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical+1.20%+6.99%-12.07%-20.30%-66.00%ARTHArch Therapeutics+3.51%+1.72%-44.86%-71.15%-63.13%NVCNNeovasc0.00%0.00%0.00%0.00%0.00%NVIVInVivo Therapeutics0.00%0.00%0.00%-49.26%-74.34%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)See this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical1.3106 of 5 stars3.53.00.00.01.10.00.6ARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical3.00Buy$10.00553.59% UpsideARTHArch TherapeuticsN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest NVIV, ARTH, NVCN, and AEMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2024AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $10.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K7.03N/AN/A$6.56 per share0.23ARTHArch Therapeutics$80K69.92N/AN/A($2.43) per share-0.49NVCNNeovasc$3.81M21.60N/AN/A$5.77 per share5.20NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$12.03M-$4.99N/AN/AN/AN/A-106.28%-86.60%6/26/2024 (Estimated)ARTHArch Therapeutics-$6.98MN/A0.00∞N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)NVCNNeovasc-$41.20M-$15.08N/A∞N/A-1,082.92%-127.25%-80.31%N/ANVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ALatest NVIV, ARTH, NVCN, and AEMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/20/2024Q1 2024ARTHArch TherapeuticsN/A-$0.57-$0.57-$0.57N/A$0.05 million2/14/2024Q3 2024AEMDAethlon Medical-$1.23-$1.37-$0.14-$1.37N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/AARTHArch TherapeuticsN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A3.933.93ARTHArch TherapeuticsN/A0.160.04NVCNNeovasc0.802.962.85NVIVInVivo TherapeuticsN/A14.3014.30OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%ARTHArch Therapeutics6.91%NVCNNeovasc1.64%NVIVInVivo Therapeutics13.78%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical4.00%ARTHArch Therapeutics4.50%NVCNNeovascN/ANVIVInVivo Therapeutics2.45%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical152.62 million2.52 millionNo DataARTHArch Therapeutics84.74 million4.53 millionNot OptionableNVCNNeovasc492.74 millionN/ANot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableNVIV, ARTH, NVCN, and AEMD HeadlinesSourceHeadlineInterview: Emmes Mindy Leffler - are video based assessments the way forward to evaluate patients at home?outsourcing-pharma.com - April 8 at 7:38 PMGut health supplements are everywhere – but which are the best ones for *you*?msn.com - March 28 at 4:18 PMDrug discovery and global player, Cresset, moves team into Boston marking major turning pointoutsourcing-pharma.com - March 12 at 7:43 PMInVivo Therapeutics Holdings Corporationcnn.com - February 15 at 12:40 AMInVivo Therapeutics Holdings Corp.wsj.com - February 14 at 2:40 PMFirm Retention Summary: InVivo Therapeutics Holdingswsj.com - February 13 at 6:29 PMInVivo Therapeutics Holdings Corp (NVIV)investing.com - February 7 at 11:49 PMBob Langer-founded device-maker declares bankruptcybizjournals.com - February 6 at 4:38 PMWhy Is InVivo Therapeutics (NVIV) Stock Up 61% Today?investorplace.com - February 6 at 9:12 AMInVivo Therapeutics Shares Plumb New Depths After Bankruptcy Filingmarketwatch.com - February 1 at 2:09 PMSpinal Cord Injury Therapeutics Market surpass $10.7 billion by 2031 - Exclusive Report by Coherent Market Insightsprnewswire.co.uk - January 31 at 12:06 PMInVivo Therapeutics Holdings: Submission Of Matters To A Vote Of Security Holderscbonds.com - January 5 at 10:04 AMInVivo Biosystems Secures New Investment to Accelerate CRISPR Innovationpharmiweb.com - January 4 at 1:33 PMInVivo Therapeutics Holdings Corp NVIVmorningstar.com - November 10 at 7:26 AMApollo, Nimbus lead bumper week for biotech financingspharmaphorum.com - September 8 at 9:41 AMAustralia’s United Malt OKs $1-B takeover offer from France’s InVivobusiness.inquirer.net - July 2 at 10:09 PMSpinal Cord Trauma Treatment Market Analysis: Examining Trends and Forecasting Revenue Growth with an estimated CAGR 6.2% from 2023-2030marketwatch.com - June 22 at 5:14 PMRing Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategybenzinga.com - May 1 at 12:30 PMWhy InVivo Therapeutics Shares Are Plunging Todayfinance.yahoo.com - March 17 at 1:53 AMInVivo seeks longer-term control in Casino-Teract retail tie-upmsn.com - March 10 at 6:45 PMWhy Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarketmsn.com - March 10 at 6:45 PMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.66%msn.com - March 10 at 3:10 AMWhy JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionmsn.com - March 9 at 5:08 PMInVivo : INSPIRE 2.0 Study In Acute Spinal Cord Injury Fails To Meet Primary Endpointmarkets.businessinsider.com - March 9 at 5:08 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAethlon MedicalNASDAQ:AEMDAethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Arch TherapeuticsOTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.NeovascNASDAQ:NVCNNeovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.InVivo TherapeuticsNASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.